Skip to main content
placeholder image

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.

Journal Article


Abstract


  • Background

    Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers. The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into standard of care with chemotherapy in various tumours. This phase I study established the safety, tolerability and clinical pharmacokinetics of olaparib alone and in combination with bevacizumab.

    Methods

    Patients with advanced solid tumours received increasing doses of continuous oral olaparib (100, 200 and 400 mg b.i.d. capsule formulation) in combination with bevacizumab (10 mg kg(-1) intravenous q2w).

    Results

    In all, 12 patients enrolled and received treatment. The most common adverse events (AEs) related to olaparib were grade 1/2 nausea and fatigue. No haematological parameters were reported as AEs. No serious AEs related to olaparib or dose-limiting toxicities (DLTs) were reported. Three patients discontinued due to AEs, two patients discontinued both olaparib and bevacizumab and one patient discontinued olaparib. Five patients received combination treatment for over 6 months. There was no evidence that bevacizumab affected olaparib.

    Conclusion

    The combination of olaparib 400 mg b.i.d. with bevacizumab 10 mg kg(-1) q2w was generally well tolerated with no DLTs. This combination could be considered for future clinical investigation.

Publication Date


  • 2012

Citation


  • Dean, E., Middleton, M. R., Pwint, T., Swaisland, H., Carmichael, J., Goodege-Kunwar, P., & Ranson, M. (2012). Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.. British journal of cancer, 106(3), 468-474. doi:10.1038/bjc.2011.555

Web Of Science Accession Number


Start Page


  • 468

End Page


  • 474

Volume


  • 106

Issue


  • 3

Abstract


  • Background

    Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers. The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into standard of care with chemotherapy in various tumours. This phase I study established the safety, tolerability and clinical pharmacokinetics of olaparib alone and in combination with bevacizumab.

    Methods

    Patients with advanced solid tumours received increasing doses of continuous oral olaparib (100, 200 and 400 mg b.i.d. capsule formulation) in combination with bevacizumab (10 mg kg(-1) intravenous q2w).

    Results

    In all, 12 patients enrolled and received treatment. The most common adverse events (AEs) related to olaparib were grade 1/2 nausea and fatigue. No haematological parameters were reported as AEs. No serious AEs related to olaparib or dose-limiting toxicities (DLTs) were reported. Three patients discontinued due to AEs, two patients discontinued both olaparib and bevacizumab and one patient discontinued olaparib. Five patients received combination treatment for over 6 months. There was no evidence that bevacizumab affected olaparib.

    Conclusion

    The combination of olaparib 400 mg b.i.d. with bevacizumab 10 mg kg(-1) q2w was generally well tolerated with no DLTs. This combination could be considered for future clinical investigation.

Publication Date


  • 2012

Citation


  • Dean, E., Middleton, M. R., Pwint, T., Swaisland, H., Carmichael, J., Goodege-Kunwar, P., & Ranson, M. (2012). Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.. British journal of cancer, 106(3), 468-474. doi:10.1038/bjc.2011.555

Web Of Science Accession Number


Start Page


  • 468

End Page


  • 474

Volume


  • 106

Issue


  • 3